Diagnostic and Therapeutic Overview of T-Cell Lymphoma: Past, Present, and Future
This program is sponsored by The Center for Biomedical Continuing Education and supported by Allos Therapeutics, Inc., and Seattle Genetics, Inc.
| Location: |
San Diego Convention Center, Room 6DE |
| Speakers: |
Christian Gisselbrecht, MD, Hôpital Saint-Louis, Paris,France
Yuon H. Kim, MD, Stanford Cancer Institute, Stanford School of Medicine, Stanford, CA
Richard L. Piekarz, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD
Andrei R. Shustov, MD, Seattle Cancer Care Alliance, Seattle, WA
Anas Younes, MD, The University of Texas MD Anderson CAncer Center, Houston, TX
Jasmine Zain, MD, NYU Clinical Cancer Center, New York, NY
|
This symposium will bring together clinical experts to share their perspectives on the past, present, and future diagnostic and therapeutic overviews of T-cell lymphoma. The session will utilize multiple methods of participation to engage attendees and enhance the learning process, including compelling faculty presentations, clinical cases from community hematologists/oncologists, an interactive case panel discussion/debate about each case, an audience response system, and an audience question-and-answer session.
Contact: Donna Robillard, The Center for Biomedical Continuing Education
Phone: 972-692-2042
E-mail:drobillard@thecbce.com
back to top
The Care of Immune Thrombocytopenia (ITP) Patients: Advancing Quality of Life and Improving Treatment Outcomes
This program is sponsored by Hemedicus, Inc. and supported by Amgen, Inc.
| Location: |
San Diego Convention Center, Ballroom 20AB |
| Speakers: |
James B. Bussell, MD, Weill Cornell Medical College, New York, NY
David J. Kuter, MD, DPhil, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Jenny McDade, DO, St. Jude Children's Research Hospital, Memphis, TN
Douglas B. Cines, MD, University of Pennsylvania, Philadelphia, PA
Terry B. Gernsheimer, MD, University of Washington, Seattle, WA
Keith B. McCrae, MD, Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Vinod Pullarkat, MD, University of Southern California, Los Angeles, CA
|
This symposiumis structured to help hematologists address the clinical and quality-of-life issues surrounding patients with ITP. Randomized controlled trials of newly licensed agents have brought advances in this area, and new ASH treatment guidelines published in 2011 will help hematologists improve patient outcomes. This symposium will be highly interactive, incorporating numerous case studies and involving audience participation.
Contact: Robin Simak, Hemedicus, Inc.
Phone: 201-666-4700
E-mail: rsimak@hemedicus.com
back to top
Factor VIII Inhibitors in Hemophilia A: Contemporary Perspectives
This program is sponsored by University of Cincinnati Office of Continuing Medical Education and supported by Grifols USA, LLC.
| Location: |
San Diego Convention Center, Room 31 |
| Speakers: |
Jan Astermark, MD, PhD, Skåne University Hospital, Malmö, Sweden
Nadia P. Ewing, MD, City of Hope, Duarte, CA
Margaret A. Heisel Kurth, MD, Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN
Pier M. Mannucci, MD, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Kathleen P. Pratt, PhD, Puget Sound Blood Center, Seattle, WA
Guy Young, MD, University of Southern California, Los Angeles, CA
|
This symposium will take a detailed look at the problem of inhibitor development – alloantibodies against infused factor VIII – in patients with hemophilia A. Development of such neutralizing alloantibodies can greatly complicate therapy and have profoundly adverse effects on patient outcome.
Contact: Carol Ann Goode, The Exeter Group
Phone: 212-644-1017
E-mail: carol.goode@exeter-group.com
back to top
Myelofibrosis: An Old Disease with New Developments
This program is sponsored by Hemedicus, Inc. and supported by Incyte Corporation.
| Location: |
Manchester Grand Hyatt San Diego, Manchester Ballroom |
| Speakers: |
Kenneth Kaushansky, MD, Stony Brook University, Stony Brook, NY
Jean-Jacques Kiladjian, MD, PhD, Hôpital Saint-Louis and Université de Paris, Paris, France
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
John McCarty, MD, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
Ruben Mesa, MD, Mayo Clinic, Scottsdale, AZ
|
Until recently, little progress had been made in the standard treatments for myeloproliferative neoplasms (MPNs), including myelofibrosis, since Dr. William Dameshek classified the Philadelphia-negative MPNs 60 years ago. In fact, the Food and Drug Administration has yet to approve a treatment with an indication specific to myelofibrosis. This symposium will provide a more complete understanding of myelofibrosis and discuss treatment options beyond palliation, including targeted pathway inhibitors, immunomodulation, and epigenetic agents.
Contact: Robin Simak, Hemedicus, Inc.
Phone: 201-666-4700
E-mail: rsimak@hemedicus.com
back to top
Epigenetics in Hematologic Malignancies: Pathogenesis and Therapy
This program is sponsored by Postgraduate Institute for Medicine and supported by Millennium: The Takeda Oncology Company, Celgene Inc., Allos Therapeutics, and the Leukemia & Lymphoma Society.
| Location: |
Manchester Grand Hyatt San Diego, Elizabeth Ballroom |
| Speakers: |
Stephen B. Baylin, MD, The Johns Hopkins University, Baltimore, MD
James E. Bradner, MD, Dana Farber-Cancer Institute, Harvard Medical School, Boston, MA
Jonathan D. Licht, MD, Feinberg School of Medicine, Northwestern University, Evanston, IL
Ross L. Levine, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
Jean-Pierre Issa, MD, The University of Texas MD Anderson Center, Houston, TX
|
Epigenetics is the study of alterations in gene expression caused by mechanisms other than changes in DNA sequence. This symposium will explore how epigenetic changes contribute to malignant transformation in blood cancers. Current research in the epigenetics of blood cancers will be discussed, as well as how that research may be applied to new treatments for leukemia, lymphoma, and multiple myeloma. A special focus will be placed on integrating current, state-of-the-art epigenetic research into clinical practice in order to improve patient outcomes.
Contact: Jeanne Fryar, Robert Michael Educational Institute, LLC
Phone: 856-672-3354
E-mail:jfryar@rmei.com
back to top
International Hematologic Oncology Tumor Board: Practical Perspectives on Current Challenging Cases of Non-Hodgkin Lymphoma (Part One of a Two-Part Series)
This program is sponsored by Research to Practice and supported by Mundipharma International Limited, Cephalon, Inc., Millennium: The Takeda Oncology Company, Celgene Corporation, and Genentech BioOncology/Biogen Idec.
| Location: |
Manchester Grand Hyatt San Diego, Douglas Pavilion |
| Speakers: |
Martin Dreyling, MD, PhD, University Hospital Campus Grosshadern, Munich, Germany
Alessandra Ferrajoli, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Stephanie A. Gregory, MD, Rush University Medical Center, Chicago, IL
Julie M. Vose, MD, The Nebraska Medical Center, Omaha, NE
Andrew D. Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY
Pier Luigi Zinzani, MD, University of Bologna, Bologna, Italy
|
Research to Practice has devised a unique case-based symposia series that will explore the nuances of therapeutic decision making and address the current clinical ambiguities and multidisciplinary challenges faced by oncologists and hematologists around the globe routinely caring for patients with non-Hodgkin lymphoma (Part One) and multiple myeloma (Part Two).
Contact: Sylvia Eriksen, Research to Practice
Phone: 305-400-7345
E-mail:seriksen@researchtopractice.com
back to top
Decisions in Community Hematology: Planning Ahead for Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphoma
This program is sponsored by Medscape, LLC, and supported by Otsuka America Pharmaceuticals, Inc.
| Location: |
Manchester Grand Hyatt San Diego, Randle Room |
| Speakers: |
Robert Soiffer, MD, Dana-Farber Cancer Institute, Boston, MA
Koen van Besien, MD, University of Chicago, Chicago, IL
Ginna Laport, MD, Stanford University Medical Center, Palo Alto, CA
Philip Bierman, MD, University of Nebraska Medical Center, Omaha, NE
Ajay Gopal, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
|
The overall objective of this program is to educate hematologists and oncologists about the importance of incorporating early planning for potential hematopoietic stem cell transplantation (HSCT) into the treatment algorithm for patients with non-Hodgkin lymphoma (NHL). The program will increase clinicians’ knowledge about the role of HSCT as part of the overall management strategy for the types of NHL most commonly seen in the community practice setting: follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.
Contact: Natasha McGrath, XpO
Phone: 212-624-3893
E-mail: nmcgrath@medscape.net
back to top
Clinical Controversies in T-Cell Lymphoma
This program is sponsored by Hemedicus, Inc., and supported by Seattle Genetics, Inc, Kyowa Hakko Kirin, Spectrum Pharmaceuticals, Ziopharm Oncology, and Millennium: The Takeda Oncology Company.
| Location: |
San Diego Convention Center, Room 6A |
| Speakers: |
Francine M. Foss, MD, Yale Cancer Center, New Haven, CT
James O. Armitage, MD, University of Nebraska Medical Center, Omaha, NE
Madeleine Duvic, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Lauren C. Pinter-Brown, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA
Kensei Tobinai, MD, PhD, National Cancer Center Hospital, Tokyo, Japan
Steven M. Horwitz, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
|
In the past, physicians faced the difficulty of a lack of available therapies when treating patients with peripheral T-cell lymphoma (PTCL); today, the difficulty is matching the patient with the best regimen to achieve an optimal and durable response. This symposium, with its focus on real-life case studies and lively discussion, will help clinicians advance from yesterday’s treatment regimens to today’s treatment strategies.
Contact: Robin Simak, Hemedicus, Inc.
Phone: 201-666-4700
E-mail:rsimak@hemedicus.com
back to top
